Literature DB >> 7662849

Assessment of individual and population bioequivalence using the probability that bioavailabilities are similar.

R Schall1.   

Abstract

In this paper a new method for the assessment of both individual and population bioequivalence is proposed that is derived from the approach of Schall and Luus (1993, Statistics in Medicine 12, 1109-1124). The method considers the probability that the bioavailability of the test product is close to the bioavailability of the reference product, against the probability that the bioavailability of the reference product is close to itself when administered on different occasions. The method can accommodate unequal variances of the bioavailabilities of the test and reference formulations, as well as formulation by subject interaction. It is thus as general and comprehensive as the methods proposed by Sheiner (1992, Statistics in Medicine 11, 1777-1778) and Schall and Luus (1993), but the resulting bioequivalence criteria are simple and easy to interpret.

Mesh:

Substances:

Year:  1995        PMID: 7662849

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  6 in total

1.  Limits for the scaled average bioequivalence of highly variable drugs and drug products.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi
Journal:  Pharm Res       Date:  2003-03       Impact factor: 4.200

Review 2.  Evaluation of bioequivalence for highly variable drugs with scaled average bioequivalence.

Authors:  Laszlo Tothfalusi; Laszlo Endrenyi; Alfredo Garcia Arieta
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

3.  Towards a practical strategy for assessing individual bioequivalence. Food and Drug Administration Individual Bioequivalence Working Group.

Authors:  R Schall; R L Williams
Journal:  J Pharmacokinet Biopharm       Date:  1996-02

4.  Individual bioequivalence. New concepts in the statistical assessment of bioequivalence metrics. FDA Individual Bioequivalence Working Group.

Authors:  R N Patnaik; L J Lesko; M L Chen; R L Williams
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

5.  Measuring switchability and prescribability: when is average bioequivalence sufficient?

Authors:  W W Hauck; S Anderson
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

6.  Trapezoid bioequivalence: A rational bioavailability evaluation approach on account of the pharmaceutical-driven balance of population average and variability.

Authors:  Sara Soufsaf; Fahima Nekka; Jun Li
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-03-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.